{"id":"W2263474571","doi":"10.1016/j.jval.2015.03.1051","title":"Cost-effectiveness of Secukinumab compared to current treatments for the treatment of moderate to severe plaque Psoriasis in Canada","year":2015,"lang":"en","type":"article","venue":"Value in Health","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":false,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Secukinumab; Ustekinumab; Medicine; Etanercept; Adalimumab; Infliximab; Ixekizumab; Psoriasis; Quality-adjusted life year; Cost effectiveness; Dermatology; Internal medicine; Psoriatic arthritis; Disease; Tumor necrosis factor alpha","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007487176,0.0002961606,0.0008191769,0.0008462701,0.000968374,0.001673788,0.001044,0.0006473578,0.00471665],"category_scores_gemma":[0.005494283,0.0002653985,0.001593748,0.001841802,0.0005625983,0.0004075842,0.0005496005,0.001026013,0.0001067689],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.07422357,"about_ca_system_score_gemma":0.0636232,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.984763,"about_ca_topic_score_gemma":0.9902928,"domain_scores_codex":[0.9985851,0.000338673,0.00009595644,0.0001012348,0.0004852202,0.0003938072],"domain_scores_gemma":[0.99718,0.0005462821,0.000343189,0.00003675016,0.0009543096,0.0009394571],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.06123031,0.002793299,0.5610194,0.003979522,0.005524332,0.0009619544,0.0007886137,0.03396587,0.001853132,0.009685447,0.04928905,0.2689091],"study_design_scores_gemma":[0.009209059,0.003785759,0.930564,0.001440803,0.005445237,0.000586932,0.002211645,0.03058884,0.0008271047,0.001147147,0.01399172,0.0002017586],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.953966,0.01804696,0.0002092792,0.007881079,0.000232515,0.0002306523,0.00779074,0.00003253974,0.01161026],"genre_scores_gemma":[0.9929783,0.003779955,0.0002095581,0.0004319573,0.00003917435,0.00002623926,0.001027415,0.000007531056,0.001499945],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07422357,"threshold_uncertainty_score":0.5385323,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1295162757465326,"score_gpt":0.3380785299799811,"score_spread":0.2085622542334485,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}